Faced with a shortened financial runway and trial recruitment obstacles caused by the COVID-19 crisis, Nordic Nanovector ASA will cut staff by 20% and pause all clinical activities other than its key pivotal PARADIGME study which is evaluating lead asset Betalutin (177Lu lilotomab satetraxetan) in third-line relapsed/refractory follicular lymphoma.
Job Cuts As Nordic Nanovector Extends Cash Runway
Biotech’s Priority Is Pivotal Betalutin Study But COVID-19 Uncertainty Remains
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
More from Business
More from Scrip
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.